Crandall, CJ; Mehta, JM; Manson, JE (7 February 2023). “Management of Menopausal Symptoms: A Review.”. JAMA329 (5): 405-420. doi:10.1001/jama.2022.24140. PMID36749328.
Langer, RD; Hodis, HN; Lobo, RA; Allison, MA (February 2021). “Hormone replacement therapy – where are we now?”. Climacteric24 (1): 3–10. doi:10.1080/13697137.2020.1851183. PMID33403881.
“The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory, Panel (1 July 2022). “The 2022 hormone therapy position statement of The North American Menopause Society.”. Menopause (New York, N.Y.)29 (7): 767-794. doi:10.1097/GME.0000000000002028. PMID35797481.
Stefanick, Marcia L. (December 2005). “Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration”. The American Journal of Medicine118 (12): 64–73. doi:10.1016/j.amjmed.2005.09.059.
Crandall, CJ; Mehta, JM; Manson, JE (7 February 2023). “Management of Menopausal Symptoms: A Review.”. JAMA329 (5): 405-420. doi:10.1001/jama.2022.24140. PMID36749328.
Langer, RD; Hodis, HN; Lobo, RA; Allison, MA (February 2021). “Hormone replacement therapy – where are we now?”. Climacteric24 (1): 3–10. doi:10.1080/13697137.2020.1851183. PMID33403881.
“The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory, Panel (1 July 2022). “The 2022 hormone therapy position statement of The North American Menopause Society.”. Menopause (New York, N.Y.)29 (7): 767-794. doi:10.1097/GME.0000000000002028. PMID35797481.